S225: ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY
Philipp Berning(University Hospital Münster), Bertram Glaß(Helios Hospital Berlin-Buch), Avichai Shimoni, Dai‐Hong Liu(Chinese PLA General Hospital), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Gerald Wulf(University of Göttingen), Francisco López Jiménez(Mayo Clinic), Eva Wagner-Drouet(Johannes Gutenberg University Mainz), Ben Carpenter(The Royal Free Hospital), Xiao‐Jun Huang(Peking University), Hélène Labussière Wallet(Hospices Civils de Lyon), Jaime Sanz(Hospital Universitari i Politècnic La Fe), Christian Reinhardt(University of Duisburg-Essen), Mi Kwon(Hospital General Universitario Gregorio Marañón), Feng‐Rong Wang(Anhui University), Ibrahim Yakoub‐Agha(Inserm), Maud Ngoya, Lucile Couronné(Inserm), Olivier Hermine(Centre National de la Recherche Scientifique), Laure Philippe(Assistance Publique – Hôpitaux de Paris), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Peter Dreger(Heidelberg University), Yves Chalandon(University of Geneva), Xi Zhang(Army Medical University), Depei Wu(Soochow University), Won-Seog Kim(Samsung Medical Center), Ariane Boumendil(Inserm), H Finel(European Society for Blood and Marrow Transplantation), Norbert Schmitz(University Hospital Münster)
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k